Alopecia areata
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Alopecia areata ti wa ni ri lori pada ti awọn scalp. Ni awọn ọran aṣoju, o han lojiji pẹlu oju didan patapata ati iwọn ti 2-3 cm.
References
Alopecia areata jẹ ipo kan nibiti eto ajẹsara rẹ kọlu awọn follicle irun rẹ, eyiti o yori si pipadanu irun igba diẹ laisi aleebu. O le ṣe afihan bi awọn abulẹ ti pipadanu irun tabi ni ipa lori gbogbo awọ-ori tabi ara rẹ, ni ipa nipa 2% ti awọn eniyan ni diẹ ninu awọn ipele ninu aye wọn. Aṣebi akọkọ dabi pe o jẹ idinku ninu idaabobo adayeba ni ayika awọn irun irun.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata jẹ ipo kan nibiti eto ajẹsara yoo kolu awọn irun ori, ti o nfa pipadanu irun si ori ori ati awọn ẹya ara irun miiran. O kan ni ayika 2% ti awọn eniyan ni agbaye. Lakoko ti o le waye ni eyikeyi ọjọ ori, o wọpọ julọ ni awọn ọmọde ju awọn agbalagba lọ (1. 92% vs. 1. 47%) . Awọn obinrin, paapaa awọn ti o ju 50 lọ, ṣọ lati ni iriri diẹ sii ju awọn ọkunrin lọ. Abẹrẹ corticosteroids taara sinu awọn agbegbe ti o kan ti fihan awọn abajade to dara julọ ju lilo wọn ni oke.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata ni a gbagbọ pe o jẹ arun autoimmune ti o ni ibatan pẹlu eto ajẹsara ti awọn follicle irun. Ilana ti o wa ni ipilẹ jẹ ikuna nipasẹ ara lati ṣe idanimọ awọn sẹẹli tirẹ, pẹlu iparun ti ajẹsara ti o tẹle ti follicle irun.
○ Itọju - Oògùn OTC
Diẹ ninu awọn eniyan ti o ni alopecia areata kekere gba pada laarin ọdun kan laisi itọju. Sibẹsibẹ, ọpọlọpọ eniyan ni iriri awọn atunṣe ni awọn aaye laileto lori awọ-ori.
#Hydrocortisone cream
○ Itọju
Awọn abẹrẹ sitẹriọdu intralesional jẹ itọju ti o munadoko julọ. Imunotherapy le ṣe idanwo ti awọn agbegbe nla ti awọ-ori ba ni ipa.
#Triamcinolone intralesional injection
#DPCP immunotherapy